Add this topic to your myFT Digest for news straight to your inbox
Appointment catapults pharma executive into leading role in US healthcare industry
Former chief of GlaxoSmithKline joins Hatteras Venture Partners
GSK’s chief has vowed to focus its research: easier said than done
Lack of access is a problem that affects rich and poor countries alike
Emma Walmsley’s smaller salary reflects lack of CEO experience
Drugmaker posts strong full-year results ahead of Sir Andrew Witty’s departure
Political attacks have raised the pressure on drugmakers
BoE’s Haldane among senior figures to attack executive pay plans
The reaction has been so negative as to leave the PM’s initiative dead in the water
Sanofi and GSK chiefs expect efforts to continue to curb rises in the US
Weak pound helps third-quarter sales surge 23%
Critics say outgoing chief neglected core business while supporters say group primed for growth
Critical questions centre on drugmaker’s shape and strategy
Sir Andrew Witty to step down from helm of Britain’s biggest pharmaceuticals group in 2017
Demand for new drugs drives production boost at sites in Durham, Hertfordshire and Angus
International Edition